The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company reported half-year revenue up 22% to US$477 million and a strong gross margin improvement to 55%. Adjusted EBITDA surged 146% year-on-year to US$52 million.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Revenue rose 22% year-on-year to US$477 million, tracking to the upper end of FY26 guidance.
- Gross margin climbed to 55%, with Precision Medicine segment margin at 65%.
- Adjusted EBITDA came in at US$52 million, up 146% on the prior year.
- Profit after tax was US$38 million, including a US$40 million payment from Regeneron.
- Group R&D investment was US$124 million, mainly supporting late-stage programs.
- Positive operating cash flow of US$23 million and cash balance of US$252 million at 30 June 2026.
What else do investors need to know?
Telix announced a new strategic collaboration with Regeneron to develop and commercialise next-generation radiopharmaceutical therapies, contributing US$40 million in other income this half. The company also completed refinancing of its convertible bond structure with a new US$600 million issue due 2031.
Operationally, the Precision Medicine segment drove growth with flagship products Illuccix and Gozellix gaining market share. Key clinical milestones were achieved, including enrolment completion for late-stage trials and regulatory progress in the US, China, Europe, and Japan. Telix is also expanding its global manufacturing footprint with new and upgraded facilities in Australia, Belgium, Japan, and the US.
What did Telix Pharmaceuticals management say?
Managing Director and Group CEO, Dr Christian Behrenbruch, said:
Telix delivered an outstanding first half, with strong revenue growth, market share gains and significant progress across clinical and regulatory milestones. Our strengthened balance sheet is enabling increased investment in late-stage programs, including ProstACT Global, market expansion opportunities within our precision medicine portfolio and manufacturing and supply chain capabilities that differentiate Telix. With multiple near-term catalysts, we enter the second half with strong momentum and confidence.
What's next for Telix Pharmaceuticals?
Telix reaffirmed FY26 revenue and other income guidance above US$1 billion, with R&D expenditure expected between US$230 million and US$270 million. The company expects ongoing clinical trial readouts and regulatory submissions in key territories later in the year.
Strategically, Telix will leverage its expanded manufacturing capacity and commercial partnerships to support commercial growth and pipeline advancement. The new at-the-market equity facility is intended to provide flexible access to capital to underpin future expansion, subject to regulatory approvals.
Telix Pharmaceuticals share price snapshot
The Telix Pharmaceuticals share price has recorded a small decline over the past 12 months, compared with a 1.5% gain from the S&P/ASX 200 index (ASX: XJO).
